$0.65
3.87% today
Nasdaq, Apr 01, 06:45 pm CET
ISIN
US6402681083
Symbol
NKTR
Sector
Industry

Nektar Therapeutics Stock price

$0.68
-0.16 19.05% 1M
-0.62 47.69% 6M
-0.25 26.88% YTD
-0.22 24.79% 1Y
-4.71 87.38% 3Y
-17.17 96.19% 5Y
-10.32 93.82% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.06 7.90%
ISIN
US6402681083
Symbol
NKTR
Sector
Industry

Key metrics

Market capitalization $126.55m
Enterprise Value $65.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.67
P/S ratio (TTM) P/S ratio 1.29
P/B ratio (TTM) P/B ratio 2.08
Revenue growth (TTM) Revenue growth 9.22%
Revenue (TTM) Revenue $98.43m
EBIT (operating result TTM) EBIT $-129.92m
Free Cash Flow (TTM) Free Cash Flow $-177.18m
Cash position $255.23m
EPS (TTM) EPS $-0.58
P/E forward negative
P/S forward 1.90
EV/Sales forward 0.99
Short interest 4.76%
Show more

Is Nektar Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Nektar Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Nektar Therapeutics forecast:

5x Buy
56%
3x Hold
33%
1x Sell
11%

Analyst Opinions

9 Analysts have issued a Nektar Therapeutics forecast:

Buy
56%
Hold
33%
Sell
11%

Financial data from Nektar Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
98 98
9% 9%
100%
- Direct Costs 31 31
9% 9%
31%
68 68
20% 20%
69%
- Selling and Administrative Expenses 72 72
4% 4%
74%
- Research and Development Expense 121 121
6% 6%
123%
-126 -126
1% 1%
-128%
- Depreciation and Amortization 4.39 4.39
44% 44%
4%
EBIT (Operating Income) EBIT -130 -130
4% 4%
-132%
Net Profit -119 -119
57% 57%
-121%

In millions USD.

Don't miss a Thing! We will send you all news about Nektar Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nektar Therapeutics Stock News

Neutral
PRNewsWire
12 days ago
SAN FRANCISCO , March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: H.C.
Neutral
Seeking Alpha
20 days ago
Nektar Therapeutics (NASDAQ:NKTR ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard Robin - President & Chief Executive Officer Brian Kotzin - Interim Chief Medical Officer Jonathan Zalevsky - Chief Research & Development Officer Sandra Gardiner - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sand...
Neutral
PRNewsWire
20 days ago
SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023.
More Nektar Therapeutics News

Company Profile

Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The firm focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.

Head office United States
CEO Howard Robin
Employees 61
Founded 1990
Website www.nektar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today